Ovarian cancer screening and early detection in the general population.

Keywords

Medicine, Ovarian cancer, Case fatality rate, Disease, Incidence (geometry)

References

• CA 125 in Benign Gynecological ConditionsH. Meden, A. Fattahi-Meibodi — 1998
• Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.Collaborative Group on Epidemiological Studies of Ovarian Cancer — 2008
• Transvaginal Sonographic Characterization of Ovarian Disease: Evaluation of a New Scoring System to Predict Ovarian MalignancyA M Sassone, Ilan E. Timor‐Tritsch, A Artner — 1991
• The CA 125 tumour-associated antigen: a review of the literature.Ian Jacobs, Robert C. Bast — 1989
• Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models.Ben W. Mol, Dorry Boll, Maartje De Kanter — 2001
• Results From Four Rounds of Ovarian Cancer Screening in a Randomized TrialEdward E. Partridge, Aimée R. Kreimer, Robert T. Greenlee — 2009
• Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.Daniel Ford — 1994
• Tubal Ligation, Hysterectomy, and Risk of Ovarian Cancer: A Prospective StudySusan E. Hankinson — 1993
• Ovarian cancer screening with annual transvaginal sonographyJohn R. van Nagell, Paul D. DePriest, Frederick R. Ueland — 2007
• Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.Steven J. Skates — 2003
• Pattern recognition of pelvic masses by gray‐scale ultrasound imaging: the contribution of Doppler ultrasoundL. Valentin — 1999
• The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.John R. van Nagell, Paul D. DePriest, Mark B. Reedy — 2000
• Cancer of the ovary.S A Cannistra — 1993
• Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.Ian Jacobs, A. Davies, Jackie Bridges — 1993
• Simple adnexal cysts: the natural history in postmenopausal women.Deborah Levine, Barbara B. Gosink, S I Wolf — 1992
• Worldwide burden of gynaecological cancer: the size of the problem.Rengaswamy Sankaranarayanan, Jacques Ferlay — 2006
• Molecular genetics for the clinicianD. J. H. Brock, Gerald A. Fishman — 1993
• The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?Vladimir Nossov, M. Amneus, Feng Su — 2008
• Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system.Jodi P. Lerner, Ilan E. Timor‐Tritsch, Alex D. Federman — 1994
• Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter studyE. Ferrazzi, Gerardo Zanetta, D. Dordoni — 1997

Cited by

• In 2014, can we do better than CA125 in the early detection of ovarian cancer?Александр Александрович Дюльдев — 2014
• Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal MassesEva María Castro Caridad — 2016
• T-CELL TREATMENTS FOR SOLID AND HEMATOLOGICAL TUMORSD. Deniger — 2013
• Large‐scale profiling of metabolic dysregulation in ovarian cancerChaofu Ke, Yan Hou, Haiyu Zhang — 2014
• Genomic Aberrations at the 3q and 14q loci: Investigation of Key Players in Ovarian and Renal Cancer BiologyPunashi Dutta — 2015
• Reduced expression of HSP27 following HAD-B treatment is associated with Her2 downregulation in NIH:OVCAR-3 human ovarian cancer cells.KUO CHU LI, Kyun Heo, NITIN AMBADE — 2015
• Overexpression of PIWI proteins in human stage III epithelial ovarian cancer with lymph node metastasisChao Chen, Jianhua Liu, Guoxiong Xu — 2013
• HE4 combined with CA125: favorable screening tool for ovarian cancerNasrin Ghasemi, Samira Ghobadzadeh, Mahnaz Zahraei — 2013
• Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascitesMarina Jakimovska, Katarina Černe, Ivan Verdenik — 2014
• High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo.Jiao Xu, Min Yong, Jia Li — 2015
• Depletion of ascorbic acid impairs NK cell activity against ovarian cancer in a mouse model.Jee‐Eun Kim, Hang-Sun Cho, Hoon-Shik Yang — 2012
• Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinomaShanshan Yang, Yunyan Zhang, Fanling Meng — 2013
• Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling PathwaysDonavon Charles Hiss — 2012
• Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancerShanshan Yang, Huiyan Li, Yunduo Liu — 2013
• High level of WAVE1 expression is associated with tumor aggressiveness and unfavorable prognosis of epithelial ovarian cancer.Jing Zhang, Liangdan Tang, Liyuan Shen — 2012
• Short hairpin RNA-mediated MDR1 gene silencing increases apoptosis of human ovarian cancer cell line A2780/taxolHui Xu, Fanzhen Hong, Li Su — 2012
• The diagnostic efficacy of nectin 4 expression in ovarian cancer patientsEnas Samir Nabih, Fayda Ibrahim Abdel Motaleb, Fekria Ahmed Salama — 2014
• Methylation of cell-free circulating DNA in the diagnosis of cancerKristina Warton, Goli Samimi — 2015
• Activin and inhibin, estrogens and NFκB, play roles in ovarian tumourigenesis is there crosstalk?Ann E. Drummond, Peter J. Fuller — 2012
• Down-Regulation of Gli Transcription Factor Leads to the Inhibition of Migration and Invasion of Ovarian Cancer Cells via Integrin β4-Mediated FAK SignalingQi Chen, Rong Xu, Chunyan Zeng — 2014

Related papers

• Ovarian CancerMarc Rubin, Christopher D. Stephen — 1993
• A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massRichard G. Moore, D. Scott McMeekin, Amy Brown — 2008
• Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trialIan Jacobs, Usha Menon, Andy Ryan — 2016
• The biology of ovarian cancer: new opportunities for translationRobert C. Bast, Bryan T. Hennessy, Gordon B. Mills — 2009
• [Screening methods for malignant ovarian tumors in adult women].Vera Milenković, Radmila Sparić, Jasmina Atanacković — 2005
• Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial SpecimensDaniel W. Cramer, Robert C. Bast, Christine D. Berg — 2011
• The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.Ingegerd Hellström, John Raycraft, Martha Hayden-Ledbetter — 2003
• Abstract ED06-02: Circulating ovarian cancer biomarkers and early detectionAndrew K. Godwin — 2013
• Screening for ovarian cancer.F Guidozzi — 1996